Farrow Jeffrey S Form 4 Global Blood Therapeutics / Jeffrey S Farrow ownership change

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Farrow Jeffrey S

(Last)

(First)

(Middle)

C/O GLOBAL BLOOD THERAPEUTICS, INC.

181 OYSTER POINT BLVD.

(Street)

SOUTH SAN FRANCISCO

94080

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Global Blood Therapeutics, Inc. [ GBT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
10/05/2022

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	10/05/2022		D		26,739	D	⁽¹⁾⁽²⁾	0	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Restricted Stock Units	⁽³⁾	10/05/2022		D			3,125	⁽⁴⁾	⁽⁴⁾	Common Stock	3,125	⁽⁴⁾	0	D
Restricted Stock Units	⁽³⁾	10/05/2022		D			9,060	⁽⁴⁾	⁽⁴⁾	Common Stock	9,060	⁽⁴⁾	0	D
Restricted Stock Units	⁽³⁾	10/05/2022		D			13,814	⁽⁴⁾	⁽⁴⁾	Common Stock	13,814	⁽⁴⁾	0	D
Restricted Stock Units	⁽³⁾	10/05/2022		D			15,460	⁽⁴⁾	⁽⁴⁾	Common Stock	15,460	⁽⁴⁾	0	D
Restricted Stock Units	⁽³⁾	10/05/2022		D			26,454	⁽⁵⁾	⁽⁵⁾	Common Stock	26,454	⁽⁵⁾	0	D
Restricted Stock Units	⁽³⁾	10/05/2022		D			42,400	⁽⁶⁾	⁽⁶⁾	Common Stock	42,400	⁽⁶⁾	0	D
Stock Option (Right to Buy)	$14.96	10/05/2022		D			120,000	⁽⁷⁾	⁽⁷⁾	Common Stock	120,000	⁽⁷⁾	0	D
Stock Option (Right to Buy)	$16.4	10/05/2022		D			10,299	⁽⁷⁾	⁽⁷⁾	Common Stock	10,299	⁽⁷⁾	0	D
Stock Option (Right to Buy)	$59.6	10/05/2022		D			35,000	⁽⁷⁾	⁽⁷⁾	Common Stock	35,000	⁽⁷⁾	0	D
Stock Option (Right to Buy)	$48.44	10/05/2022		D			40,000	⁽⁷⁾	⁽⁷⁾	Common Stock	40,000	⁽⁷⁾	0	D
Stock Option (Right to Buy)	$65.82	10/05/2022		D			38,500	⁽⁷⁾	⁽⁷⁾	Common Stock	38,500	⁽⁷⁾	0	D
Stock Option (Right to Buy)	$44.48	10/05/2022		D			38,739	⁽⁷⁾	⁽⁷⁾	Common Stock	38,739	⁽⁷⁾	0	D
Stock Option (Right to Buy)	$29.87	10/05/2022		D			28,628	⁽⁷⁾	⁽⁷⁾	Common Stock	28,628	⁽⁷⁾	0	D

Explanation of Responses:

1. This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 7, 2022, by and among the Issuer, Pfizer Inc., a Delaware corporation ("Parent"), and Ribeye Acquisition Corp., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer, with the Issuer surviving the merger as a wholly owned subsidiary of Parent (the "Merger"), effective as of the effective time of the Merger (the "Effective Time") on October 5, 2022. At the Effective Time, each share of the Issuer's common stock, par value $0.001 per share ("Common Stock"), reported in this Form 4 was converted into the right to receive $68.50 in cash (the "Merger Consideration"), without interest and subject to any required tax withholding, upon the terms and subject to the conditions of the Merger Agreement.

2. (Continued from Footnote 1) From and after the Effective Time, all such shares of Common Stock were no longer outstanding and were automatically canceled.

3. Each (i) restricted stock unit of the Issuer subject only to service-based vesting requirements ("RSU") and (ii) restricted stock unit of the Issuer subject to performance-based vesting requirements ("PSU") represented a contingent right to receive one share of Common Stock.

4. Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding RSU was canceled and converted into the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such RSU immediately prior to the completion of the Merger multiplied by (ii) the Merger Consideration.

5. Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding PSU was canceled and converted into the right to receive an amount in cash equal to (i) (x) with respect to a PSU subject to vesting based on the Issuer's relative total shareholder return, approximately 199.5% of the target number of shares of Common Stock subject to such PSU immediately prior to the Effective Time and (y) with respect to a PSU subject to vesting based on the Issuer's relative percentage of patient share, the target number of shares of Common Stock subject to such PSU immediately prior to the Effective Time, in each case multiplied by (ii) the Merger Consideration. Includes 8,786 additional shares of Common Stock deemed vested as of immediately prior to the Effective Time in accordance with the preceding sentence.

6. Each outstanding PSU tied to a price hurdle with respect to a share of Common Stock (and not relative total shareholder return) was forfeited at the Effective Time.

7. Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option.

Remarks:

	/s/ Miguel Carrillo, Attorney-in-Fact	10/06/2022
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Farrow Jeffrey S Form 4Global Blood Therapeutics / Jeffrey S Farrow ownership change